TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03732066

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Text Messages
Description: Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Text Messages
Description: Usual text messages four times a week, including cardiovascular knowledge and follow-up reminders, such as risk factors for CHD and typical symptoms of myocardial infarction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Reminders
Description: 1. The mHealth tools will provide special interventions according to the patients' medical history. For example, patients with hypertension will receive daily reminders on blood pressure measurement and medication. They will also receive early warning on hypertension with a systolic blood pressure of \>180 mmHg or \<90 mmHg. Patients who smoke will be required to quit smoking. Every patient will receive a Health Report monthly, which will reflect their drug compliance, blood pressure and so on.~2. Drug Reminders: Patients' medication information will be recorded by obtaining pictures of their medication. Patients will be asked to punch time clocks simply in the mHealth tools. If they forget to punch cards, they can punch cards whenever they think of it. If there is no record of medication for 3 days, SMS alerts will be received, and phone calls will be received over 7 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Responses
Description: 1. Auto-Response: After sending personal or discomfort symptom questions, the patients will be provided with an automatic response pushed by the back-end database by crawling the keywords. It is suggested that the answer is just for reference. In case of urgent questions, they will be advised to consult the clinicians.~2. The researchers will communicate with the patients every month.
Study: NCT04516265

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neurodevelopmental treatment
Description: A personally designed treatment program will be applied in line with the principles of neurodevelopmental treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: video-based trunk training
Description: Games developed for the use of children with cerebral palsy will be used for trunk training.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-based trunk training will apply with Theratogs
Description: Video-based trunk training will apply with Theratogs
Study: NCT03069625

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-to-stand test
Description: CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 6-Minute Walk Test
Description: CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
Study: NCT04277754

Intervention type: OTHER
Intervention: Observational
Description: To Observe and describe motor and visual development
Study: NCT04268420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP013
Description: Falciparum Malaria Protein-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP013
Description: Falciparum Malaria Protein-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP013
Description: Falciparum Malaria Protein-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP013
Description: Falciparum Malaria Protein-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FMP013
Description: Falciparum Malaria Protein-13

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study: NCT01297738

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal size increase with HS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal frequency increase with HFHS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal frequency increase with HS
Description: On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
Study: NCT00288431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: administered at 60 mg/m2 intravenously every 3 weeks
Study: NCT00501748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
Study: NCT00877526

Intervention type: OTHER
Intervention: No treatment given
Description: Subject will only fill out a questionaire when entering the observational study.
Study: NCT03222180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
Study: NCT04268420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study: NCT00550511

Intervention type: RADIATION
Group type: OTHER
Intervention: Surgeon-performed ultrasound
Description: After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
Study: NCT00867659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrotide acetate
Description: cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
Study: NCT04268420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALF with QS-21, saponin molecule derived from the tree bark of Quillaja species
Study: NCT03945981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir + Lamivudine FDC
Description: Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets
Study: NCT02610699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional otoscope
Description: The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
Study: NCT03405025

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endoscopic ultrasound guided radiofrequency ablation
Description: To establish if radiofreuqency ablation of aldosterone producing adrenal adenomas can be carried out via the endoscopic route and to assess safety of the procedure.

Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound
Description: ultrasound
Study: NCT04092309

Intervention type: DRUG
Group type: OTHER
Intervention: ACE inhibitor, Sacubitril-Valsartan
Description: Search for Protective effect after chemotherapy and bone marrow transplantation
Study: NCT02610699

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional otoscope
Description: The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone otoscope
Description: The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone otoscope
Description: The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
Study: NCT01157533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
Study: NCT03730948

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: DC vaccine for colorectal cancer
Study: NCT03454555

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared Decision Making
Description: The Shared Decision Making (SDM) intervention is a patient-provider communication intervention to explore and compare treatment options, assess a patient's values and preferences, and reach a shared decision about chronic pain treatment. The intervention will have both clinician and patient educational components. The content of the clinician component will be based on the Agency for Healthcare Research and Quality's SHARE: Seek, Help, Assess, Reach, Evaluate Approach, which is a 5-step process for shared decision making that includes exploring and comparing the benefits, harms, and risks of each option through meaningful dialogue about what matters most to the patient. Participants randomized to Arm 1 will have their study visits and opioid use managed by an SDM-trained clinician at their practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain
Description: The Motivational Interviewing and Cognitive Behavioral Therapy for Chronic Pain (MI+CBT-CP) intervention is an empirically based behavioral pain management behavioral therapy intervention, including MI to enhance motivation for active participation in the CBT-CP, and the use of CBT-CP to enhance pain coping skills. One individual MI session will focus on patient engagement and enhancing a patient's own intrinsic motivation for CBT-CP participation. MI will also be woven into the group CBT-CP sessions. We will deliver 8 sessions of CBT-CP, as is standard in a group setting, in-person or virtually.
Study: NCT02872636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal catheter insertion with extracorporeal filtration of CSF
Description: Extracorporeal filtration of CSF
Study: NCT04092309

Intervention type: DRUG
Group type: OTHER
Intervention: ACE inhibitor, Sacubitril-Valsartan
Description: Search for Protective effect after chemotherapy and bone marrow transplantation

Intervention type: DRUG
Group type: OTHER
Intervention: ACE inhibitor, Sacubitril-Valsartan
Description: Search for Protective effect after chemotherapy and bone marrow transplantation
Study: NCT03996811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise education
Description: weekly telephone consultations concerning exercise. we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
Study: NCT02532686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAAOI-2
Description: 500-2000mg/d, oral, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, for 6 weeks
Study: NCT03520257

Intervention type: DRUG
Group type: OTHER
Intervention: Apatinib
Description: Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib, a small molecule anti-angiogenic targeted drug that has been demonstrated to be safe and effective after failure of standard chemotherapy for advanced gastric cancer, has been initially successful in phase II clinical trials for the treatment of unresectable advanced HCC patients. The efficacy of ralfiny in the treatment of Oriental population (ORIENTAL study) is better. The randomized, double-blind, multi-center phase III clinical study of apatinib second-line treatment of advanced hepatocellular carcinoma showed a good efficacy and safety. Currently, Phase III clinical studies of apatinib in HCC patients undergoing systemic chemotherapy or sorafenib treatment have progressed. Initial results also showed good efficacy and safety.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy of tumors and portal vein tumor thrombi can promote further tumor shrinkage, and at the same time, the physiological basis for the recanalization of the original tumor thrombus itself will result in necrosis and fibrosis of the tumor thrombus, completely blocking the blood supply to the tumor portal vein. As a result, blood supply to the other side of the portal vein increases, and hepatocyte regeneration in a healthy liver is promoted, so that the patient can obtain surgical opportunities.
Study: NCT03233893

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: light activated calcium silicate
Description: for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light activated calcium silicate
Description: for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.~for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration.
Study: NCT01618448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tolvaptan 15mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01458665

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional arthroscopic rotator cuff repair
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with PRP
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.
Study: NCT00381979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Expressive Therapy
Study: NCT02248987

Intervention type: OTHER
Intervention: patients treated with antipsychotics

Intervention type: OTHER
Intervention: patients treated with antipsychotics

Intervention type: OTHER
Intervention: patients treated with antipsychotics
Study: NCT03044028

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica Orthopedics QB1 e-vive™ system
Description: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica Orthopedics QB1 e-vive™ system
Description: a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
Study: NCT04534452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl (Sinus Comfort, BAY112476)
Description: 30 mg Extended Release Tablets, single oral dose
Study: NCT01834534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CarePartners for depression
Description: Automated telephone calls for depression monitoring and self-management support.
Study: NCT02601014

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given 1 mg/kg IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given 1 mg/kg IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given 3 mg/kg IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given 3 mg/kg IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: given orally per standard of care
Study: NCT00619723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active medication in appearance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
Study: NCT03854760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: anesthesiologist with limited experiment
Description: Using the simulate device, the trainees are going to trained and evaluated the ability of driving bronchoscopy in simulate device and clinical practice.
Study: NCT04384094

Intervention type: DEVICE
Intervention: Esthesiometer measurement
Description: Measuring the corneal sensitivity using rebound technology.
Study: NCT02696291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 30 mg oral solution
Description: UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 75 mg oral solution
Description: UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 150 mg oral solution
Description: UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B X mg (dose to be determined) oral solution
Description: UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B Y mg (dose to be determined) oral solution
Description: UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days